5. Alimera Sciences ( ALIM) is a biopharmaceutical company that specializes in the research, development and commercialization of prescription ophthalmic pharmaceuticals, focusing on diseases affecting the back of the eye, or retina. The company will announce its first quarter results on May 5.

Net loss for the first quarter of 2011 is forecast at $6.7 million, or 20 cents per share, compared to net income of $2.6 million, or 12 cents per share, according to analysts polled by Bloomberg.

The stock was recently upgraded from an underperform rating to a neutral rating by analysts at Zacks Investment Research. All the six analysts covering the stock rate a buy on it. Analysts polled by Bloomberg foresee 48% upside for the stock over the next 12 months with a consensus target price of $13. The stock has already gained a whopping 152% during the past one year and currently trades at a P/E of 18.6

If you liked this article you might like

Nuance to Buy Transcend Services for $29.50 a Share: News Alert

5 Small-Cap Growth Stocks With Zero Debt

Small-Caps Have an Edge for the Second Half

Small-Caps Have an Edge for the Second Half

Health-Care Reformer: Under the Radar

Health-Care Reformer: Under the Radar

Small-Cap Tech Stocks With Big Potential

Small-Cap Tech Stocks With Big Potential